Skip to main content
. 2021 Apr 23;11:633034. doi: 10.3389/fonc.2021.633034

Table 1.

Comparison of Characteristics Between Patients with ccRCC and RAML-wvf.

Patients with ccRCC (n = 93) Patients with RAML-wvf (n = 49) P
Age 57 (33–84) 54 (26–90) 0.267
Gender <0.001
 Male 67 (72.0) 18 (36.7)
 Female 26 (28.0) 31 (63.3)
Amount 1
 Single 88 (94.6) 46 (93.9)
 Multiple 5 (5.4) 3 (6.1)
Growth pattern 0.163
 Pattern A 20 (21.5) 13 (26.5)
 Pattern B 71 (76.3) 32 (65.3)
 Pattern C 2 (2.2) 4 (8.2)
 Pattern D 0 (0) 0 (0)
Contour 0.175
 Regular 69 (74.2) 31 (63.3)
 Irregular 24 (25.8) 18 (36.7)
Edge 0.184
 Blurred 35 (37.6) 13 (26.5)
 Clear 58 (62.4) 36 (73.5)
Wedge shape sign <0.001
 No 82 (88.2) 29 (59.2)
 Yes 11 (11.8) 20 (40.8)
Round tumor-kidney interface 0.353
 No 76 (81.7) 43 (87.8)
 Yes 17 (18.3) 6 (12.2)
Pseudocapsule <0.001
 No 25 (26.9) 45 (91.8)
 Yes 68 (73.1) 4 (8.2)
Necrosis or cystic <0.001
 No 30 (32.3) 40 (81.6)
 Yes 63 (67.7) 9 (18.4)
Calcification 1
 No 90 (96.8) 46 (95.8)
 Yes 3 (3.2) 2 (3.2)
Heterogeneous tumor parenchyma in pre-enhancement scanning 0.002
 No 74 (79.6) 48 (98.0)
 Yes 19 (20.4) 1 (2.0)
Degree of CT attenuation in pre-enhancement scanning <0.001
 Not-high 63 (67.7) 3 (6.1)
 High 30 (32.3) 46 (93.9)
Enhancement in pre-enhancement scanning <0.001
 Homogeneous 26 (28.0) 34 (69.4)
 Heterogeneous 67 (72.0) 15 (30.6)
Enhancement in CMP <0.001
 Homogeneous 7 (7.5) 35 (71.4)
 Heterogeneous 86 (92.5) 14 (28.6)
Enhancement in NP <0.001
 Homogeneous 18 (19.4) 41 (83.7)
 Heterogeneous 75 (80.6) 8 (16.3)
ESR 1 <0.001
 <1–1 44 (47.3) 43 (87.8)
 ≥1 49 (52.7) 6(12.2)
ESR 2 0.011
 <1 78 (83.9) 48 (98.0)
 ≥1 15 (16.1) 1(2.0)
Enhancement pattern <0.001
 Fast-in-fast-out 76 (81.7) 20 (40.8)
 Fast-in-slow-out 10 (10.8) 21 (42.9)
Persistent enhancement 7 (7.5) 8 (16.3)